Skip to main content
SpringerLink
Log in

Intraperitoneal Drug Delivery of Antineoplastics

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The administration of antineoplastic agents directly into the peritoneal cavity as treatment of localised cancer is based on sound pharmacokinetic principles. This unique technique has to the potential to optimise outcome in settings where preclinical and clinical data suggest that cytotoxicity of a specific drug against a particular tumour type is enhanced by either increasing the drug concentration or duration of exposure.

Phase I trials have confirmed the safety and pharmacokinetic advantage for a number of agents delivered by the intraperitoneal relative to the systemic route, including cisplatin (10- to 20-fold advantage for regional delivery), carboplatin (10- to 20-fold advantage), and paclitaxel (1000-fold advantage). In phase II rials, performed mostly in patients with ovarian cancer, this approach has achieved objective responses in settings where intravenous drug delivery has not achieved the desired effect (e.g. surgically documented complete response using intraperitoneal cisplatin as second-line therapy of ovarian cancer). Phase III trials employing intraperitoneal cisplatin as initial treatment of small volume advanced ovarian cancer have demonstrated that regional therapy results in a modest, but statistically significant, improvement in both progression-free and overall survival compared to intravenous cisplatin.

Further exploration of this novel method of treatment, including the conduct of definitive randomised phase III clinical trials, is indicated in ovarian cancer and in other tumour types where clinical manifestations are principally localised to the peritoneal cavity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 1955; 159: 1704–7

    Article  PubMed  CAS  Google Scholar 

  2. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1–9

    PubMed  CAS  Google Scholar 

  3. Alberts DS, Young L, Mason N, et al. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 1985; 12 (3 Suppl. 4): 38–42

    PubMed  CAS  Google Scholar 

  4. Markman M. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Crit Rev Oncol Hematol 1993; 14: 15–28

    Article  PubMed  CAS  Google Scholar 

  5. Markman M. Intraperitoneal chemotherapy. Crit Rev Oncol Hematol 1999; 31: 239–46

    Article  PubMed  CAS  Google Scholar 

  6. Howell SB, Pfeifle CE, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982; 97: 845–51

    PubMed  CAS  Google Scholar 

  7. Casper ES, Kelsen DP, Alcock NW, et al. Ip cisplatin in patients with malignant ascites: pharmacokinetics evaluation and comparison with the iv route. Cancer Treat Rep 1983; 67: 325–38

    Google Scholar 

  8. DeGregorio MW, Lum BL, Holleran WM, et al. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol 1986; 18: 235–38

    Article  PubMed  CAS  Google Scholar 

  9. Elferink F, van der Vijgh WJF, ten Bokkel Huinink WW, et al. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 1988; 21: 57–60

    Article  PubMed  CAS  Google Scholar 

  10. Markman M, Rowinsky E, Hakes T, et al. Phase 1 trial of intraperitoneal taxol: a Gynecologic Oncology Group Study. J Clin Oncol 1992; 10: 1485–91

    PubMed  CAS  Google Scholar 

  11. Francis P, Rowinsky E, Schneider J, et al. Phase 1 feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 1995; 13: 2961–7

    PubMed  CAS  Google Scholar 

  12. Ozols RF, Young RC, Speyer JL, et al. Phase 1 and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 1982; 42: 4265–9

    PubMed  CAS  Google Scholar 

  13. Markman M, George M, Hakes T, et al. Phase 2 trial of intraperitoneal mitoxantrone in the management of refractory ovarian carcinoma. J Clin Oncol 1990; 8: 146–50

    PubMed  CAS  Google Scholar 

  14. Monk BJ, Surwit EA, Alberts DS, et al. Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery. Semin Oncol 1988; 15: 27–31

    PubMed  CAS  Google Scholar 

  15. Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329: 1550–9

    Article  PubMed  CAS  Google Scholar 

  16. Markman M, Reichman B, Hakes T, et al. Responses to secondline cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991; 9: 1801–5

    PubMed  CAS  Google Scholar 

  17. Markman M, Berek JS, Blessing JA, et al. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based IP chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of IP cisplatin and recombinant alpha-interferon. Gynecol Oncol 1992; 45: 3–8

    Article  PubMed  CAS  Google Scholar 

  18. Markman M, Blessing JA, Major F, et al. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group Study. Gynecol Oncol 1993; 50: 191–5

    Article  PubMed  CAS  Google Scholar 

  19. West GW, Weichselbau R, Little JB. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 1980; 40: 3665–8

    PubMed  CAS  Google Scholar 

  20. Durand RE. Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res 1981; 41: 3495–8

    PubMed  CAS  Google Scholar 

  21. Ozols RF, Locker GY, Doroshow JH, et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979; 39: 3209–14

    PubMed  CAS  Google Scholar 

  22. Nederman T, Carlsson J. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 1984; 13: 131–5

    Article  PubMed  CAS  Google Scholar 

  23. Los G, Mutsaers PHA, van der Vijgh WJF, et al. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989; 49: 3380–4

    PubMed  CAS  Google Scholar 

  24. Markman M, Brady MF, Spirtos NM, et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998; 16: 2620–4

    PubMed  CAS  Google Scholar 

  25. Berek JS, Markman M, Stonebraker B, et al. Intraperitoneal interferon-a in residual ovarian carcinoma: a phase II Gynecologic Oncology Group Study. Gynecol Oncol 1999; 75: 10–14

    Article  PubMed  CAS  Google Scholar 

  26. Pujade-Lauraine E, Guastalla J-P, Colombo N, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996; 14: 343–50

    PubMed  CAS  Google Scholar 

  27. Edwards RP, Gooding W, Lembersky BC, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 1997; 15: 3399–3407

    PubMed  CAS  Google Scholar 

  28. Markman M. Is there a role for intraperitoneal therapy in the management of gastrointestinal malignancies? Cancer Invest 1995; 13(6): 625–8

    Article  PubMed  CAS  Google Scholar 

  29. Markman M, Cleary S, Pfeifle CE, et al. Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 1986; 58: 18–21

    Article  PubMed  CAS  Google Scholar 

  30. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992; 118: 547–50

    Article  PubMed  CAS  Google Scholar 

  31. Sugarbaker PH, Zhu B-W, Sese GB, et al. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993; 36: 323–9

    Article  PubMed  CAS  Google Scholar 

  32. Howell SB, Zimm S, Markman M, et al. Long term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987; 5: 1607–12

    PubMed  CAS  Google Scholar 

  33. Markman M, Reichman B, Hakes T, et al. Impact on survival of surgically-defined favorable responses to salvage intraperitoneal chemotherapy in small volume residual ovarian cancer. J Clin Oncol 1992; 10: 1479–84

    PubMed  CAS  Google Scholar 

  34. Piver MS, Recio FO, Baker TR, et al. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer. Cancer 1994; 73: 1693–8

    Article  PubMed  CAS  Google Scholar 

  35. Barakat RR, Almadrones L, Venkatraman ES, et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol 1998; 69: 17–22

    Article  PubMed  CAS  Google Scholar 

  36. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950–5

    Article  PubMed  CAS  Google Scholar 

  37. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451–67

    Article  Google Scholar 

  38. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6

    Article  PubMed  CAS  Google Scholar 

  39. Markman M, Bundy BN, Alberts DS, et al. Randomized phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume small III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001–7

    PubMed  CAS  Google Scholar 

  40. Shapiro F, Schneider J, Markman M, et al. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. Gynecol Oncol 1997; 67: 39–45

    Article  PubMed  CAS  Google Scholar 

  41. Sugarbaker PH, Gianola FJ, Speyer JC, et al. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 1985; 98: 414–21

    PubMed  CAS  Google Scholar 

  42. Hagiwara A, Takahashi T, Kojima O, et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992; 339: 629–31

    Article  PubMed  CAS  Google Scholar 

  43. Rosen HR, Jatzko G, Repse S, et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998; 16: 2733–38

    PubMed  CAS  Google Scholar 

  44. Wansik Y, Whang I, Suh I, et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998; 228: 347–54

    Article  Google Scholar 

  45. Los G, Verdegaal EME, Mutsaers PHA, et al. Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 1991; 28: 159–65

    Article  PubMed  CAS  Google Scholar 

  46. Markman M, Reichman B, Hakes T, et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small volume residual ovarian cancer. Gynecol Oncol 1993; 50: 100–4

    Article  PubMed  CAS  Google Scholar 

  47. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 1997; 89: 480–7

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Cleveland Clinic Taussig Cancer Center, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio, 44195, USA

    Maurie Markman

Authors
  1. Maurie Markman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurie Markman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M. Intraperitoneal Drug Delivery of Antineoplastics. Drugs 61, 1057–1065 (2001). https://doi.org/10.2165/00003495-200161080-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161080-00003

Keywords

Search

Navigation